DK1240186T3 - Forbedringer i eller relateret til immunrespons mod HIV - Google Patents

Forbedringer i eller relateret til immunrespons mod HIV

Info

Publication number
DK1240186T3
DK1240186T3 DK00985690.7T DK00985690T DK1240186T3 DK 1240186 T3 DK1240186 T3 DK 1240186T3 DK 00985690 T DK00985690 T DK 00985690T DK 1240186 T3 DK1240186 T3 DK 1240186T3
Authority
DK
Denmark
Prior art keywords
hiv
immune response
immunogen
synthetic polypeptide
protein
Prior art date
Application number
DK00985690.7T
Other languages
English (en)
Inventor
Tomas Hanke
Andrew James Mcmichael
Original Assignee
Medical Res Council
Int Aids Vaccine Initiative
Univ Nairobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930294.5A external-priority patent/GB9930294D0/en
Priority claimed from GB0025234A external-priority patent/GB0025234D0/en
Application filed by Medical Res Council, Int Aids Vaccine Initiative, Univ Nairobi filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1240186T3 publication Critical patent/DK1240186T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DK00985690.7T 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV DK1240186T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930294.5A GB9930294D0 (en) 1999-12-23 1999-12-23 Improvements in or relating to immune responses to HIV
GB0025234A GB0025234D0 (en) 2000-10-14 2000-10-14 Improvements in or relating to immune responses to HIV
PCT/GB2000/004984 WO2001047955A2 (en) 1999-12-23 2000-12-22 Improvements in or relating to immune responses to hiv

Publications (1)

Publication Number Publication Date
DK1240186T3 true DK1240186T3 (da) 2010-05-31

Family

ID=26245157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00985690.7T DK1240186T3 (da) 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV

Country Status (16)

Country Link
US (1) US7993651B2 (da)
EP (1) EP1240186B1 (da)
JP (1) JP4805511B2 (da)
CN (1) CN1213068C (da)
AT (1) ATE457996T1 (da)
AU (1) AU784679B2 (da)
BR (1) BR0016510A (da)
CA (1) CA2392877C (da)
CY (1) CY1110917T1 (da)
DE (1) DE60043856D1 (da)
DK (1) DK1240186T3 (da)
ES (1) ES2341429T3 (da)
HK (1) HK1058048A1 (da)
MX (1) MXPA02006379A (da)
PT (1) PT1240186E (da)
WO (1) WO2001047955A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU1194802A (en) 2000-03-02 2001-12-11 Univ Emory DNA expression vectors and methods of use
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
PL207168B1 (pl) * 2001-09-20 2010-11-30 Glaxo Group Ltd Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
ATE520708T1 (de) * 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
EP1675613B1 (en) * 2003-09-15 2012-05-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Hiv vaccines based on env of multiple clades of hiv
CA2539864A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
CN1968710B (zh) * 2004-06-01 2013-12-25 默沙东公司 HIV gp41融合中间体的稳定的肽模拟物
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2006020071A2 (en) * 2004-07-16 2006-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccines against aids comprising cmv/r-nucleic acid constructs
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1856143A2 (en) * 2005-02-24 2007-11-21 Medical Research Council Hivcon: anhiv immunogen and uses thereof
US8119144B2 (en) 2006-06-02 2012-02-21 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
WO2010096561A1 (en) * 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
AU2010305030A1 (en) * 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012062873A2 (en) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
ES2807173T3 (es) 2012-09-10 2021-02-22 Int Aids Vaccine Initiative Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015138698A1 (en) * 2014-03-12 2015-09-17 Temple University-Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
WO2017156170A1 (en) 2016-03-09 2017-09-14 University Of Massachusetts Use of modified hiv-1 for generating fully human antibodies
CA3145833A1 (en) * 2019-07-02 2021-01-07 Roman YELENSKY Hiv antigens and mhc complexes
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2869063B2 (ja) * 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン ＬＡＶに対する抗体と免疫的に反応性であるｇａｇによりコードされたペプチドの発現及び使用
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5175098A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV
US5175097A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US5134227A (en) * 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
US5993819A (en) * 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
ATE134195T1 (de) * 1988-06-10 1996-02-15 United Biomedical Inc Peptidfragmente von hiv
US5817318A (en) * 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
US5210181A (en) * 1989-05-15 1993-05-11 Akzo N.V. T-lymphotropic retrovirus peptide
GB8918200D0 (en) * 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2025634A1 (en) 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
DE69231705T2 (de) * 1992-06-04 2001-10-18 Univ Osaka Res Found Gag-Env Fusion-Antigen aus HIV
AU677225B2 (en) * 1992-10-06 1997-04-17 Dade Behring Marburg Gmbh Retrovirus from the HIV group and its use
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
US6225045B1 (en) * 1996-05-13 2001-05-01 Ribotargets, Ltd. Assays for screening for inhibitors of HIV
CN1233187A (zh) * 1996-08-09 1999-10-27 病毒技术公司 HIVp－17肽片段、含有该片段的组合物及其制造和使用方法
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
WO1998043669A1 (en) * 1997-04-03 1998-10-08 Thomas Jefferson University Chimeric viral proteins
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU6139699A (en) 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
CA2350911A1 (en) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1088889A1 (en) * 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage

Also Published As

Publication number Publication date
HK1058048A1 (en) 2004-04-30
JP2003518931A (ja) 2003-06-17
ATE457996T1 (de) 2010-03-15
DE60043856D1 (de) 2010-04-01
WO2001047955A2 (en) 2001-07-05
US7993651B2 (en) 2011-08-09
AU2208901A (en) 2001-07-09
JP4805511B2 (ja) 2011-11-02
CN1213068C (zh) 2005-08-03
CA2392877A1 (en) 2001-07-05
US20030108562A1 (en) 2003-06-12
WO2001047955A3 (en) 2002-05-10
BR0016510A (pt) 2002-08-27
EP1240186B1 (en) 2010-02-17
CN1434831A (zh) 2003-08-06
CA2392877C (en) 2011-11-15
MXPA02006379A (es) 2004-06-21
EP1240186A2 (en) 2002-09-18
ES2341429T3 (es) 2010-06-21
CY1110917T1 (el) 2015-06-10
PT1240186E (pt) 2010-03-25
AU784679B2 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
DK1240186T3 (da) Forbedringer i eller relateret til immunrespons mod HIV
Haigwood et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies
Rusche et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
Albert et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
Fast et al. Human trials of experimental AIDS vaccines
WO2004075850A2 (en) Polyvalent immunogen
Berzofsky Development of artificial vaccines against HIV using defined epitopes
CA2077651C (en) Peptides stimulating cytotoxic t cells immune to hiv rt
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Clerici et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
LOLEIT et al. Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
WO1998041536A9 (en) Glycosylation deficient siv and hiv envelope glycoproteins
WO1998041536A1 (en) Glycosylation deficient siv and hiv envelope glycoproteins
BÖTTIGER et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
OA10271A (en) Multiple branch peptide constructions for use against hiv
DE69217614D1 (de) Hybride, lösliche und nicht gespaltene gp160-variante
WO2005016952A2 (en) Polyvalent immunogen
Okuda et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection
NARDELLI et al. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections